| Nov 14 |
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
|
| Nov 14 |
An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued
|
| Nov 13 |
Corvus Pharmaceuticals: The Market Likes The Story
|
| Nov 13 |
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...
|
| Nov 13 |
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Corvus Pharmaceuticals GAAP EPS of -$0.60 misses by $0.48
|
| Nov 12 |
Corvus: Q3 Earnings Snapshot
|
| Nov 12 |
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
Corvus Pharmaceuticals Q3 2024 Earnings Preview
|
